Huapont Life Sciences (SHE:002004) obtained drug registration from China's medical products administrator for ibrutinib tablets, according to a weekend filing with the Shenzhen bourse.
The drug is indicated for mantle cell lymphoma, chronic lymphocytic leukemia and Waldenström's macroglobulinemia.
The company said this marks its first self-developed innovative drug to receive NMPA registration.
Shares of the chemical products manufacturer closed 2% higher Monday.